Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease

Last updated: May 22, 2023
Sponsor: University Hospital Southampton NHS Foundation Trust
Overall Status: Active - Recruiting

Phase

N/A

Condition

Mild Cognitive Impairment

Alzheimer's Disease

Dementia

Treatment

N/A

Clinical Study ID

NCT05579236
RHM NEU0402
NIHR202146
  • Ages 50-90
  • All Genders

Study Summary

The aim of this study is to find out whether a new image analysis technique called Cortical Disarray Measurement (CDM) could be used to help better diagnose Alzheimer's disease. This study will see whether changes on CDM can be used to identify Alzheimer's disease from a group of people living with memory and thinking problems. The study will also explore how CDM relates to changes in memory or thinking over time.

Eligibility Criteria

Inclusion

PATIENT PARTICIPANTS Inclusion Criteria:

  • Diagnosis of mild cognitive impairment (MCI) or prodromal Alzheimer's Disease (AD) asdefined by National Institute on Ageing/Alzheimer's Association (NIA/AA) diagnosticcriteria for MCI/prodromal AD, NOT including MCI unlikely due to AD; OR, Diagnosis ofAlzheimer's disease as defined by NIA/AA criteria for probable AD
  • Clinical dementia rating (CDR) scale global score of very mild or mild (0.5 or 1)impairment
  • Ability to undergo and tolerate MRI scans, with no contraindications to MRI
  • Ability to tolerate blood draws
  • Ability to give informed consent to participate in the study

Exclusion

Exclusion Criteria:

  • Do not meet the inclusion criteria
  • No study companion available
  • Individuals with a non-progressive learning disability
  • Pregnant or intending to become pregnant during the study COMPANION PARTICIPANTS Inclusion Criteria:
  • Aged over 18 years
  • Sufficient knowledge on study participant's condition to complete companionassessments of the patient, in the investigator's judgement
  • Able and willing to attend all clinical visits for completion of companion assessmentsor provide the relevant assessments remotely via phone or video call Exclusion Criteria:
  • A condition or reason, in the investigator's judgement, that would question thevalidity of the acquired companion reported data
  • Individuals who are not fluent in English

Study Design

Total Participants: 400
Study Start date:
September 28, 2022
Estimated Completion Date:
April 30, 2025

Study Description

This is a multi-centre observational longitudinal cohort study to evaluate and optimise the Cortical Disarray Measurement (CDM) technique for diagnosis and prognosis in patients with mild cognitive impairment and prodromal / mild Alzheimer's Disease. CDM is a novel MRI analysis tool that quantifies cortical and regional diffusion tensor imaging signals in grey matter to observe pathological changes related to neurodegeneration. Participants in this study will be monitored for 2 years.

Research Aims:

  • Assess the accuracy of CDM in detecting progressive change in cognitive and functional measures over 2 years in participants presenting with mild cognitive impairment or early dementia.

  • Determine the relationship between CDM (both cross-sectionally and longitudinally) and change on standard cognitive and functional assessment measures.

  • Explore patient and companion views and experiences of the diagnostic journey for dementia and their views on CDM implementation.

  • To explore the costs and consequences of introducing CDM-augmented MRI as a form of early diagnosis of Alzheimer's disease in people presenting with MCI or mild AD compared to current practice.

Connect with a study center

  • University Hospital Southampton NHS Foundation Trust

    Southampton, Hampshire SO16 6YD
    United Kingdom

    Active - Recruiting

  • Dorset Healthcare University NHS Foundation Trust

    Bournemouth,
    United Kingdom

    Site Not Available

  • Cardiff and Vale University Health Board

    Cardiff,
    United Kingdom

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.